NCT02975440 is a Phase 1 clinical trial of Rifampicin in Endometriosis, sponsored by Bayer.

Who is sponsoring NCT02975440?

NCT02975440 is sponsored by Bayer.

What drugs are being tested in NCT02975440?

Interventions in NCT02975440: Rifampicin, Midazolam, BAY1002670_Vilaprisan.

What condition does NCT02975440 study?

NCT02975440 studies Endometriosis.

Is NCT02975440 still recruiting?

NCT02975440 is currently completed. Last updated 2 July 2017.

Last reviewed 2017-07-02 · How we verify

NCT02975440

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan

Completed Phase 1 Last updated 2 July 2017

What this trial tests

Phase 1 trial testing Rifampicin in Endometriosis in 12 participants. Completed in 11 April 2017.

Timeline

10 November 2016

Primary endpoint
27 January 2017

11 April 2017

Quick facts

Lead sponsor	Bayer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	12
Start date	10 November 2016
Primary completion	27 January 2017
Estimated completion	11 April 2017
Sites	1 location across Germany

Drugs / interventions tested

Rifampicin (Rifampicin) — full drug profile →
Midazolam (midazolam) — full drug profile →
BAY1002670_Vilaprisan — full drug profile →

Conditions studied

Endometriosis — all drugs for Endometriosis →

Sponsor

Bayer — full company profile →

Who can join

Adults 45 to 65, female only, with Endometriosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be conducted in a single center, open-label study with a single group fixed sequence design to evaluate the effect of repeated oral administration of 600 mg RIF(Rifampicin) given once daily over 11 days on the single oral dose pharmacokinetics of VPR(Vilaprisan) and on MDZ(Midazolam) as a reference (probe) substance.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans.
Chattopadhyay N, Kanacher T, Casjens M, Frechen S, et al · · 2018 · cited 19× · PMID 30171692 · DOI 10.1111/bcp.13750
Enhancing of cerebral Abeta clearance by modulation of ABC transporter expression: a review of experimental approaches.
Loeffler DA. · · 2024 · cited 2× · PMID 38872626 · DOI 10.3389/fnagi.2024.1368200

Verify or expand the search:

Other trials of Rifampicin

Trials testing the same drug.

NCT06191692 — 1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam · Phase 3 · not yet recruiting
NCT07196449 — Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects · Phase 1 · active not recruiting
NCT06192160 — Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis · Phase 2 · recruiting
NCT05994742 — An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM · Phase 3 · active not recruiting
NCT06255951 — Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subje · Phase 1 · completed

Other recruiting trials for Endometriosis

Currently open trials in the same condition.

NCT06559852 — The Impact of Yoga on Endometriosis-Related Pain · NA · recruiting
NCT07393295 — Efficacy and Tolerability of TENS in Endometriosis-related Pain · NA · recruiting
NCT07134023 — Educational Program for the Multidisciplinary Support of Patients With Endometriosis · NA · recruiting
NCT07240883 — ENDO1000 - A UK-wide Endometriosis Research Project · recruiting
NCT06974773 — Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups · NA · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02975440 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 2 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02975440.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing